Economic downturn takes toll on incentives and raises

Results of a study conducted by ZS Associates designed to benchmark incentive practices in the pharmaceutical and biotech industries revealed an increase of 8% in total target compensation in 2009, and that variable pay as a percentage of overall target compensation remained constant at 25%.

The study, which included respondents from 44 companies representing more than 50,000 sales reps and managers, stated that companies are reacting to the economic downturn by freezing target incentives and reducing increases to base salaries.

According to the study, 53% of the companies who took action did not increase their target incentives; 29% of those reduced the rate of increase in base salaries; while 12% froze base salaries. Quota-based bonus, according to study results, continues to be the predominant component of incentive plans for sales force personnel because quote-based plans provide the fairest way to address differential territory potential and do not create competition between reps if properly implemented. 

According to the study, companies have also had to improvise to deal with data restrictions such as New Hampshire's ban on the sale of prescribing data.

Stephen Redden, principal and leader of ZS Associates' Incentive Compensation Practice said that compensation patterns are unlikely to change in the near future. “The pharma industry moves much as the general economy does and I don't see any evidence of an economic improvement,” said Redden, adding, “the general unemployment rates are continuing to increase a little bit which is going to continue to put pressure on pharma companies as well. It's probably going to get a little bit worse before it gets better, but we haven't come to that point where we've turned the corner.”
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.